Food Addiction Symptoms and Clinical Outcomes in Binge-Type Eating Disorders: A Randomized Clinical Trial of Cognitive Behavioral Therapy-Guided Self-Help in China
Abstract
Objective: Food addiction (FA) is clinically relevant in binge-type eating disorders (EDs), yet its treatment relevance remains unclear in mainland China. This study examined (1) FA's associations with ED psychopathology and psychosocial functioning; (2) FA symptom changes following cognitive behavioral therapy-guided self-help (CBT-gsh); and (3) whether FA improvement was independently associated with changes in psychosocial functioning.
Method: In this assessor-blind randomized controlled trial, 87 adults with binge-type EDs were allocated to a 10-week asynchronous web-based CBT-gsh program or a waitlist control group. Assessments occurred at baseline, post-treatment, and 1-month follow-up. FA severity was the primary outcome; secondary outcomes included ED psychopathology, binge-eating frequency, psychosocial impairment, depression/anxiety, and body mass index (BMI). Linear mixed models and hierarchical regression were used to analyze the data.
Results: At baseline, FA severity was positively associated with ED psychopathology and psychosocial impairment. All outcomes except BMI improved significantly in the intervention group (all ps < 0.001), with no changes in controls. At post-treatment, 20% of intervention participants achieved binge-eating abstinence versus 2.5% of controls, and fewer met moderate-to-severe FA criteria (Δn = -16) in the intervention group. FA reduction was independently associated with lower post-treatment psychosocial impairment (β = 0.49, p <…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 87 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.